A popular antibiotic used for treating bronchitis, pneumonia, ear infections and sexually transmitted diseases may boost the risk of death, a US study said Wednesday. Azithromycin has been on the worldwide market since the 1980s, but the study in the New England Journal of Medicine is the first to document serious heart risks — up to a 2.5-fold higher chance of cardiovascular fatalities — in the first five days of treatment compared to another or no antibiotic. The comparison was based on an examination of patient records in the southern US state of Tennessee from 1992 to 2006. Researchers at Vanderbilt University compared about 348,000 prescriptions of azithromycin to millions of records from people who were not treated with any antibiotics or who received amoxicillin, a similar medication that is considered heart safe. The analysis found there were 47 more deaths per million in those taking azithromycin compared to those on amoxicillin. When researchers examined patients already at high risk for heart problems, the chance increased to 245 additional cardiovascular deaths per million in the azithromycin group compared to the amoxicillin takers. While the relative number of fatalities was low, researchers said the findings offer new information about possible dangers that doctors and patients should consider. “We believe this study adds important information on the risk profile for azithromycin,” said lead author Wayne Ray, professor of preventive medicine at Vanderbilt University. “For patients with elevated cardiovascular risk and infections for which there are alternative antibiotics, the cardiovascular effects of azithromycin may be an important clinical consideration.” The Croatian pharmaceutical company Pliva first patented azithromycin in 1981, and later struck a worldwide deal with Pfizer to sell the antibiotic worldwide. Pfizer branded the treatment Zithromax and Zmax. Azithromycin is a macrolide antibiotic that works by stopping the growth of bacteria. Side effects may include skin rashes, itching, swelling, difficulty breathing or swallowing and rapid, pounding or irregular heartbeats, according to the American Hospital Formulary Service.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor